LENZ Therapeutics, Inc. (LENZ) SEC Filings & Earnings Calls

Commercial execution risk

“The Company has just recently begun to realize product revenue from its principal operations.” · word for word

Cash burn risk

“Net cash used in operating activities (72,295) for the six months ended June 30, 2026”

Customer concentration risk

“For the three and six months ended June 30, 2026, three of the Company's wholesaler customers each individually accounted for more than 10% of total product sales.” · word for word

High SG&A spend relative to revenue; profitability dependent on scaling.

“SG&A expenses increased to $39.4 million... primarily driven by our launch investment.” · word for word

Dependence on regulatory approvals and milestone payments from partners.

“eligible to receive up to $65 million in remaining regulatory and commercial milestone payments... MAA submitted to MHRA... New Drug Submission to Health Canada.” · word for word

High SG&A burn rate relative to revenue; net loss widening.

“SG&A $45.0M vs revenue $1.9M; net loss $41.5M.”

Dependence on successful commercial adoption of single product VIZZ.

“Only product revenue from VIZZ; no other revenue streams.”

Manufacturing process transition caused non-recurring cost of sales charge.

“Cost of sales $1.1M includes non-recurring events related to manufacturing process transition.”

Customer concentration risk

“For the three months ended March 31, 2026, the Company's three wholesaler customers each individually accounted for more than 10% of total product sales. On a combined basis, these wholesaler customers accounted for 44% of product sales” · word for word

Inventory quality risk

“During the three months ended March 31, 2026, the Company recorded an inventory write-down of $0.3 million due to inventory that fell out-of-specification in transit.” · word for word

Commercialization execution risk

“The Company has a limited operating history, and the sales and income potential of the Company’s business and market are unproven.” · word for word

Emerging growth company status expiration

“We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of Graphite’s initial public offering (i.e., December 31, 2026), (iii) the” · word for word

Commercial adoption risk

“We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision.” · word for word

Competition from existing and future presbyopia treatments

“Currently, the only FDA approved and marketed pharmaceutical treatments for presbyopia are Vuity, launched by AbbVie, Qlosi, marketed by Orasis, and a generic version of Vuity, launched by Amneal Therapeutics. In January 2026, the FDA approved Yuvezzi, which Tenpoint Therapeutics indicated may be launched in Q2 2026.” · word for word

Commercial-stage execution risk; reliance on VIZZ for revenue; competition in presbyopia market.

“First commercial product sale of VIZZ in October 2025... early stage of launch” · word for word

Preliminary unaudited results subject to adjustment

“preliminary, unaudited financial results ... subject to change upon completion of the Company’s accounting and annual audit procedures”

Potential product safety risk; adverse event could impact VIZZ adoption or regulatory scrutiny.

“Retinal tear reported in patient using VIZZ; company downplays but acknowledges real-world events may occur.”

Commercial execution risk for VIZZ

“The Company has a limited operating history, and the sales and income potential of the Company’s business and market are unproven.” · word for word

Dependence on third-party manufacturers

“The Company depends on outsourced manufacturing for the production of VIZZ for commercial use.” · word for word

Accumulated deficit and need for additional capital

“The Company has experienced net losses since its inception and, as of September 30, 2025, had an accumulated deficit of $191.2 million.” · word for word

Early commercial stage; net loss expected to continue

“Net loss $16.7M in Q3; SG&A expenses increased significantly due to launch.”

Dependence on VIZZ commercial success

“Company focused on single product launch.”